пептид ghk cu Трипептид меди (GHK-CU) Медный пептид GHK-Cu лиофилизированный порошок

Research in APP/PS1 Alzheimer's mice demonstrates that Dihexa treatment markedly reduces activation of astrocytes and microglia, the brain's primary inflammatory cells

The peptide has been extensively studied in both preclinical models and human clinical trials, demonstrating consistent fat-reducing effects with a favorable safety profile

Its dopaminergic and BDNF-mediated effects may be relevant to attention regulation pathways, making it a subject of interest in exploratory neuroscience research on focus and impulse control

Hydroxocobalamin does not have many significant drug interactions

Long-term DSIP safety has not been established through clinical trials